Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

U.S. Democrats Seek Trump’s Cooperation on Drug Price Reform

Reuters Staff  |  December 22, 2016

NEW YORK (Reuters)—A group of Democratic senators took their plans to tackle rising drug costs to President-Elect Donald Trump on Tuesday, asking him to work with them and Republicans on the issue. In a letter dated Tuesday, the 19 senators named five areas for cooperation: allowing the Medicare program to negotiate prescription prices, increasing transparency,…

Filed under:Drug Updates Tagged with:Affordable Care Act (ACA)costsDrugsMedicareObamacare

U.S. Supreme Court Declines to Hear Biologic Drug Patent Fight

Brendan Pierson  |  December 12, 2016

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday declined to hear a case over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval before bringing them to the market. The justices opted not to take up Apotex Inc.’s appeal of a July federal appeals court ruling that could…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Amgenbiologic drugsBiosimilarslawsuitLegal

New GAC Chair Picks up the Baton

Will Harvey, MD, MSc, & Angus Worthing, MD, FACR, FACP  |  December 7, 2016

It’s an honor and a thrill to be the next chair of the Government Affairs Committee. Boy, do we have a big year ahead.

Filed under:From the CollegeLegislation & Advocacy

Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

From the College  |  November 16, 2016

Although the FDA has not yet awarded the title of interchangeable to any biosimilar, legislation that governs their substitution will continue to be a dominant state issue in 2017. Since 2013, 24 states and Puerto Rico have passed legislation regarding interchangeable biologics. As many as 15 states will have biosimilar-related legislation introduced by coalitions in…

Filed under:Biologics/DMARDsDrug UpdatesFrom the College Tagged with:BiologicsdrugLegislationMedicationnotificationprescriberrheumatologystate lawssubstitutionupdate

ACR President Dr. Joan Von Feldt Reflects on Her Year in Office, Advancing Rheumatology!

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  November 16, 2016

This has been a year of tremendous growth, change and achievement for the ACR, and I have been fortunate to lead the ACR in these endeavors. The ACR and ARHP, including the ACR Executive Committee, the ACR Board of Directors, standing and special committee chairs and hundreds of dedicated volunteers, have contributed to this growth…

Filed under:President's Perspective Tagged with:American College of Rheumatology (ACR)Dr. Joan Von Feldtofficepresidentrheumatology

The Fight Against the Medicare Part B Demonstration Project

Richard Quinn  |  October 28, 2016

The ACR and 315 other organizations have publicly said savings would not be achieved by the demonstration project and that it will reduce access to care for patients…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:AdvocacyCenters for Medicare & Medicaid Services (CMS)CongressMedicareMedicare Part BMedicare ReimbursementReimbursement

Shifting Health Policy Landscape Brings Opportunities, Responsibility to Advocate for Rheumatology

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  October 10, 2016

Heraclitus of Ephesus (c. 500 BC) is credited with the saying, “The only constant is change.” Now, centuries later, change is meteoric, and especially in healthcare and health policy, the pace of change is relentless. Rheumatology and other specialties continue to face challenges that threaten the ability to deliver compassionate, competent care to patients. The…

Filed under:Legislation & AdvocacyPresident's Perspective Tagged with:AdvocacyAmerican College of Rheumatology (ACR)CongressHealthcarelegislatorsMedicarepatient carepolicyRheumatic Diseaserheumatology

Big Pharma vs. Big Pharma in Court Battles over Biosimilar Drugs

John Miller  |  October 4, 2016

ZURICH (Reuters)—The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines. These drug makers are now increasingly straddling both sides of the courtroom, too, protecting their high-price products from biosimilars—biopharmaceutical drugs with the treatment properties of medicines…

Filed under:Biologics/DMARDsDrug UpdatesLegal Updates Tagged with:AbbVieadalimumabadalimumab-attoAmgenBiosimilarsetanerceptetanercept-szzslawsuitLegalNovartis

Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

Kimberly Retzlaff  |  September 8, 2016

The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsdrug updateinfliximabprescriptionpricingrheumatologistrheumatology

Understanding Prescription Pathways for Biologic Medication Therapy

Andrew Hochradel, PharmD, & the ARHP Practice Committee  |  September 8, 2016

Executing evidence-based medicine in the U.S. is challenging, especially utilizing high-cost medications in rheumatologic care. As patients trust their clinicians to be their medical experts, clinicians must trust their care team members to be experts at implementing the care plan. A clinician’s knowledge of human anatomy and physiology is the foundation to understanding pathophysiology. From…

Filed under:Biologics/DMARDsDrug Updates Tagged with:ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)BiologicsBiosimilarspathwayspatient carePractice Managementprescription

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 31
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences